BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191107
DTEND;VALUE=DATE:20191108
DTSTAMP:20260515T022828
CREATED:20190409T073558Z
LAST-MODIFIED:20190409T073558Z
UID:20262-1573084800-1573171199@www.pharmajournalist.com
SUMMARY:The Pharma Gorilla
DESCRIPTION:After a successful and overwhelming response of the Pharma Gorilla conference Mumbai on March 27\, The Conference Gorilla is organizing its 2nd and 3rd Edition of The Pharma on following dates and venues.  \n\nThe Pharma Gorilla | June 26\, 2019 | Le Meridien Singapore\, Sentosa\nThe Pharma Gorilla | Nov 07\, 2019 | New Delhi\, India\n\n The objective of this conference to share expertise addressing the current advancements involved in the Pharmaceutical industry. The knowledgeable intriguing sessions will create an ideal platform to get acquainted with the latest trends\, advancements\, and future of the pharmaceutical sciences. It is a wonderful opportunity for all the participants as it provides a networking opportunity to collaborate with the world class Pharmaceutical and healthcare industry. \nThe conference program have been designed in such way which can cover the trending topics under Keynote session\, exclusive presentation\, product lunch\, panel and round table discussion and it also provides a meaningful information. \nThe Pharma Gorilla provides a perfect platform for conducting presentations\, keynote sessions\, sharing the knowledge\, one on one meeting with your potential audience and getting acquainted with the latest developments in the pharmaceutical and healthcare industry to stand out of the competition. \nTarget Audience: 150+ Pharma professional from all over the Asia so I think it would be a good platform for you to accomplish your networking with the key decision makers of pharmaceutical companies\, software development companies\, CRO\, manufacturing\, formulation\, digital marketing and data management companies. \nGlimpse of Conference Agenda! \nConference Panels \n\nArtificial Intelligence in Pharma and Healthcare\nA disruptive take on marketing: Digital Marketing comes to Pharma\nScope of E-Pharmacy in Asia: Bringing New Dimensions to Pharma Industry\nLatest Trends in Formulation Development: A Global Perspective\nThe Impact of Regulatory Reform on Innovation in Drug Delivery Systems\n\nRoundtable Discussion \n\nImproving patient engagement and experience to improve clinical trials\n\nKeynote Session \n\nInnovation-driven and emerging technologies of Pharma Industry in Asia\nThe Global Pharma Industry: Policies\, Regulations and Key Trends 2019-2020\n\nExclusive Presentation \n\nRole of IPR in pharmaceutical industry\nCareer Growth Opportunities in the pharmaceutical industry\nImproving Biosimilars in manufacturing data\n\nFor any query\, contact us at contact@theconferencegorilla.com or IN: +91-813-004-7071 | US: +1-347-480-1588
URL:https://www.pharmajournalist.com/event/the-pharma-gorilla-3/
LOCATION:MA
ORGANIZER;CN="The Conference Gorilla":MAILTO:contact@theconferencegorilla.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191112
DTEND;VALUE=DATE:20191116
DTSTAMP:20260515T022828
CREATED:20190213T093434Z
LAST-MODIFIED:20190214T153532Z
UID:19515-1573516800-1573862399@www.pharmajournalist.com
SUMMARY:TIDES Europe: Oligonucleotide & Peptide Therapeutics
DESCRIPTION:TIDES Europe is Europe’s #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate new products to market. \n \n400+ OLIGONUCLEOTIDE AND PEPTIDE SCIENTISTS AND EXECUTIVES\nFast-track your oligonucleotide and peptide research to the clinic and beyond by collaborating with leading pharma\, biotechs\, academia and solution providers from North America\, Asia and Europe. \n40+ CASE STUDIES AND NEW DATA PRESENTATIONS\nHear best practices\, lessons learned and important industry developments across the entire spectrum of oligonucleotide and peptide development and production. \n30+ LEADING EXHIBITORS\nConnect with leading manufacturing\, technologies\, and service providers to drive your promising therapeutic towards commercial success. \nRegister now at www.TIDESEuropeEvent.com with code “PHARMJ10” and SAVE 10%.
URL:https://www.pharmajournalist.com/event/tides-europe-oligonucleotide-peptide-therapeutics/
LOCATION:RAI Amsterdam | Amsterdam\, Netherlands
ORGANIZER;CN="Knect365 Life Sciences":MAILTO:Allison.macdonald@knect365.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191112
DTEND;VALUE=DATE:20191115
DTSTAMP:20260515T022828
CREATED:20190812T093209Z
LAST-MODIFIED:20190812T093329Z
UID:21936-1573516800-1573775999@www.pharmajournalist.com
SUMMARY:Data Analytics for Pharma Development 2019
DESCRIPTION:Following a hugely successful event in Amsterdam last year\, we’re excited to inform you that the 5th Annual Data Analytics for Pharma Development Forum will be taking place in Munich from the 13-14 November 2019. Read all about it here:  Download the 2019 Agenda. \n \nThe industry needs to move past the challenge of unstructured data sets and integrating data from multiple sources to begin to work collaboratively with other departments and organisations\, as well as create a real world evidence framework for our pharmaceutical development through effective data utilisation. This is why we’ve curated an industry leading program with inside expertise from the top. \nSo – who exactly will be there? \nScientific Director\, Janssen\nPrinciple Data Scientist\, Novo Nordisk\nPrincipal Scientist Digitalisation Lead in Large Molecule Research\, Roche\nSenior Director\, Head\, Global Real World Evidence Strategy and Analytics\, Biogen\nHealth Informatics Director\, AstraZeneca\nVice President AI and Machine Learning\, BERG Health\nDirector\, Data Science IKU in EMEA\, Celgene\nGlobal HEOR Evidence Expert Lead\, Sanofi\nHead Quantitative Sciences\, Bill & Melinda Gates Medical Research Institute \nFor the first time ever we also bring you the Start-Up Afternoon\, where 5+ innovative data-management start ups demonstrate their technology in lightning-round presentations. \nWe also know that people learn better when they’re being active\, so this year we also running Certificate Course in Data Analytics to deep-dive into data strategy\, advanced analytics and machine learning & AI to ensure you’re at the forefront of innovation. \nWe encourage the sharing of challenges and success stories through an interactive program – but most importantly\, we facilitate open discussions during networking opportunities where our delegates from Big Pharma\, biotech\, and start-ups will be looking to you to inform their next step on how to optimise their data strategy. \nWith 50+ attendees and an expert speaker faculty of over 20 senior decision makers\, the Data Analytics forum is Europe’s industry leading event. \nDownload the 2019 Agenda here to find out more about the forum
URL:https://www.pharmajournalist.com/event/data-analytics-for-pharma-development-2019/
LOCATION:Hilton Munich City\, Rosenheimer Str. 15\, München\, 81667\, Germany
ORGANIZER;CN="IQPC":MAILTO:enquire@iqpc.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191112
DTEND;VALUE=DATE:20191114
DTSTAMP:20260515T022828
CREATED:20190916T083615Z
LAST-MODIFIED:20190916T083615Z
UID:22433-1573516800-1573689599@www.pharmajournalist.com
SUMMARY:Protein Engineering Congress EU
DESCRIPTION:Most enzymes found in nature are not suitable for industrial purposes. The field of protein and enzyme engineering is growing at a rapid rate\, with competition within industries high and the need to optimise performance greater than ever. \nIntroducing the European Protein Engineering Congress\, dedicated to uncovering the new and emerging practices\, techniques and methods of protein and enzyme engineering across industries. \nWith pharmaceutical\, flavour & fragrance\, consumer goods\, animal feed\, and agrochemical sectors all approaching the design\, build and generation of new biocatalysts and molecules not found in nature\, come and learn from our line-up of leading speakers to get an update on the new technologies used in the field of strain and protein engineering.
URL:https://www.pharmajournalist.com/event/protein-engineering-congress-eu/
LOCATION:Radisson Blu Hotel Frankfurt\, Franklinstrasse 65\, 60486\, Frankfurt am Main\, Germany
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191113
DTEND;VALUE=DATE:20191115
DTSTAMP:20260515T022828
CREATED:20190731T104534Z
LAST-MODIFIED:20190731T113531Z
UID:21753-1573603200-1573775999@www.pharmajournalist.com
SUMMARY:5th annual European Microbiome Congress
DESCRIPTION:The gut microbiota’s importance in human health and disease progression spreads far wider than just gastro-intestinal conditions. The immune\, nervous and metabolic systems couple the microbiome with the rest of the body and thus play a crucial and interlinking role in extra-intestinal diseases including neurological\, cancer and metabolic conditions. \n \nFor the 5th annual European Microbiome Congress\, we’ve shifted the focus from gastro-intestinal to extra-intestinal as we examine the latest pre-clinical and clinical data demonstrating the gut microbiota’s role in some of the world’s most critical and costly diseases in modern society. \nJoin key opinion leaders from across academia and industry to examine the latest research data. This is your opportunity to find out how others plan to translate the latest understanding of the gut-microbiome into therapeutic drugs that have the power to treat cancer\, metabolic\, neurodegenerative and psychiatric disorders. \nTo learn more about 5th annual European Microbiome Congress\, and to register online\, visit https://microbiomecongress.com
URL:https://www.pharmajournalist.com/event/5th-annual-european-microbiome-congress/
LOCATION:Olympia Conference Centre\, Hammersmith Rd\, Hammersmith\, London W14 8UX
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191113
DTEND;VALUE=DATE:20191115
DTSTAMP:20260515T022828
CREATED:20190829T084945Z
LAST-MODIFIED:20190829T085516Z
UID:22152-1573603200-1573775999@www.pharmajournalist.com
SUMMARY:Skin Microbiome Congress EU
DESCRIPTION:With 2.35 billion Euros being spent on cosmetic product R&D in Europe\, and Skin Microbiome being “2019’s hottest skin care trend” – a claim supported by major market researchers and beauty bibles\, are you ready for the next generation of skin care? \nWe are bringing you the first data focused Skin Microbiome event with two concurrent tracks focused on the hard data and commercial sides of skin microbiome: \n\nData Track: focuses on the hard data that supports and legitimises product claims and drives increased understanding of the skin microbiome.\nCommercial Track: tackles the challenges faced when building a commercially viable skin microbiome company\, optimising your supply chain and executing successful marketing & communication strategies.\n\nDiscover the potential of prebiotic\, probiotic and postbiotic products being developed to protect and promote a healthy microbiome and ultimately combat dermatological conditions from acne and eczema to dandruff and skin allergies. Take advantage of: \n\nEffective Networking with 150+ innovators\, start-ups\, multinational companies and vendors.\nCutting Edge Research – Discover the latest advancement in therapeutic & cosmetic products containing live bacteria\, bacterial extracts\, or active ingredients to promote & protect the skins microbiome.\nConsumer Trends – Understand how consumer trends towards natural\, organic products and active beauty are shaping the evolution of products adapted to the skin microbiome.\nClinical Trials – Explore how to design an effective clinical trial & translate research into clinically & commercially viable therapeutics.\nCompetitive Edge – Determine how to differentiate your product line & seize this market opportunity\, gaining market share with scientifically backed products.\nRegulation – Understand the different paths to market & regulatory considerations necessary to launch a cosmetic or therapeutic product.\n\nWith an increasing consumer trend towards natural products\, what’s more natural than harnessing the bacteria on your skin? Don’t miss your chance to understand the next generation of natural skincare products!
URL:https://www.pharmajournalist.com/event/skin-microbiome-congress-eu/
LOCATION:Olympia London\, Hammersmith Road\, Kensington\, London\, W14 8UX
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T022828
CREATED:20180531T073809Z
LAST-MODIFIED:20190605T115541Z
UID:16039-1574035200-1574294399@www.pharmajournalist.com
SUMMARY:Ophthalmic Drugs
DESCRIPTION:SMi Group are pleased to present the 3rd Annual Ophthalmic Drugs Conference and Focus Day\, taking place on the 18th-20th November 2019 in London\, UK. \n \nThe global ophthalmic drug market size is expected to reach a value of $30 billion USD by 2023 with growing focus on alternative delivery approaches to replace intravitreal drug delivery and novel drug development being the key factors driving the market. \nWith this in mind\, this year’s Ophthalmic Drugs conference will explore new discoveries in the treatment of ocular rare disease; innovations in gene therapy; the challenges in drug delivery through a complex barrier; patient comfort and regulatory compliance which make up  core components within the Ophthalmic Drug sphere. \nNEW FOR 2019: \nThe brand-new Focus Day on ‘Novel Drug Delivery Through a Complex Barrier’ will bring academic perspectives on the future for ocular drug delivery and notified bodies will provide a regulatory insight into this emerging field of ophthalmic drug development. \nHow will you benefit? \nWith over 15 expert presentations\, the three-day agenda offers you peer-to-peer networking with Global Product Managers\, Heads of Drug Development\, Senior Directors of Ophthalmology\, Heads of Research and Development and many more! \nNetwork and learn from leading professionals such as: \nCHAIRS FOR 2019: \n\nMitchell de Long\, Vice President\, Chemistry\, Aerie Pharmaceuticals\nNaj Sharif\, Vice President\, Global Ophthalmology\, Santen Inc\, USA\n\nFEATURED SPEAKERS INCLUDE: \n\nParisa Zamiri\, Global Head of Clinical Development in Ophthalmology\, Novartis Pharmaceutical Inc.\nGavin Spencer\, Executive Vice President and Chief Business Officer\, Nicox\nAniz Girach\, Chief Medical Officer\, ProQR Therapeutics\nDaniel Chung\, Global Medical Strategy Lead- Ophthalmology\, Spark Therapeutics\nMichael Ehrlich\, Senior Clinical Program Lead – Retinopathies\, Boehringer Ingelheim\nPeter Morgan-Warren\, Medical Assessor\, MHRA\nWilliam Dallman\, Clinical Development Manager\, Eyenuk\n\nFor more information and to register\, visit: www.ophthalmicdrugs.com/pj \nEarly-Bird Rates \n\nBOOK BY 28TH JUNE AND SAVE £300\nBOOK BY 30TH SEPTEMBER AND SAVE £100\n\nSocial Media Handles \nFollow us on LinkedIn ‘SMi Pharma’\, Twitter @SMiPharm and use #OphthalmicDrugs \nContact Info: \nT: +44 (0) 20 7827 6164\nE: nhoward@smi-online.co.uk
URL:https://www.pharmajournalist.com/event/ophthalmic-drugs-2019/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:nhoward@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191118
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T022828
CREATED:20180905T081807Z
LAST-MODIFIED:20190717T092148Z
UID:17493-1574035200-1574294399@www.pharmajournalist.com
SUMMARY:3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) 2019
DESCRIPTION:AFDD is back for its third year as the only conference to bring together industry leaders\, clinicians and academic experts focused on finding an effective anti-fibrotic treatment. \n \nOver 3 days packed with compelling case studies\, diverse panels and varied networking opportunities\, you’ll glean insights from industry and academic leaders across fibrotic disease areas. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of anti-fibrotic drug development. \nTo learn more about this event\, and to register online\, visit https://afdd-summit.com/ \nContact:\nPhone – (+1) 617 455 4188\nEmail – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/afdd-summit-2019/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191121
DTSTAMP:20260515T022828
CREATED:20190809T095122Z
LAST-MODIFIED:20190813T105926Z
UID:21871-1574121600-1574294399@www.pharmajournalist.com
SUMMARY:1st RNA Editing Summit 2019
DESCRIPTION:  \nTranslating Emerging RNA Editing Approaches for Therapeutic Applications. \nAs CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications\, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications. \nAs the therapeutic potential of RNA editing explodes\, discover the fundamental mechanisms of RNA editing\, such as recruiting endogenous ADARs with encodable guideRNAs\, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits. With the temporary nature of RNA editing providing a huge opportunity in many areas beyond genetic diseases\, uncover how to recruit endogenous editing enzymes and ultimately deliver safe and effective transcriptome edits. \nJoin RNA\, functional genomic\, cell biology and immuno-oncology experts from large pharma\, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality. \nTo learn more about this event\, and to register online\, visit https://ter.li/jikni6
URL:https://www.pharmajournalist.com/event/1st-rna-editing-summit-2019/
LOCATION:Revere Hotel Boston Common\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191122
DTSTAMP:20260515T022828
CREATED:20190910T085210Z
LAST-MODIFIED:20190910T085210Z
UID:22357-1574121600-1574380799@www.pharmajournalist.com
SUMMARY:3rd Annual Dermatology Drug Development Summit
DESCRIPTION:The Dermatology Drug Development Summit series is a unique industry-focused forum dedicated to innovating\, accelerating and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs\, in the treatment of high unmet need. \nThe 3rd Annual Dermatology Drug Development Summit provides leading industry experts with a unique forum to debate the end-to-end challenges in dermatology drug development: from discovering new research on key disease pathways\, to unveiling critical preclinical insights\, discussing formulation strategies\, defining the optimal clinical development plans or evaluating commercialization approaches. \nJoin peers and leaders in this space for an exclusive three-day meeting of comprehensive discussion\, sharing of latest advances and pioneering insights\, and networking opportunities. \nHear from 30+ experts including: \n\nSonya Abraham\, Head of New Treatment Strategies\, Immunology\, UCB\nDavid Rubenstein\, CSO\, Dermavant Sciences\nKendall Marcus\, Director – Division of Dermatology & Dental Products\, FDA\nMichael Kuligowski\, Executive Medical Director – Inflammation & Autoimmunity\, Incyte Corporation\nJohn Harris\, Vice Chair of Dermatology & Director\, Vitiligo Clinic & research Center\, University of Massachusetts Medical School\nSuma Krishnan\, Founder & COO\, Krystal Biotech\n\nAcross an end-to-end\, comprehensive agenda\, learn from case studies on: \n\nHow to enhance preclinical activities\nThe latest advances in translational research\nHow to advance topical drug development and formulation approaches\nHow to accelerate clinical development and what are the latest clinical results\nHow to tackle the evolving regulatory and commercial landscape in dermatology\n\nFind out more here: https://ter.li/jj7wxg
URL:https://www.pharmajournalist.com/event/3rd-annual-dermatology-drug-development-summit/
LOCATION:Aloft Boston Seaport District\, Boston\, MA
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191119
DTEND;VALUE=DATE:20191122
DTSTAMP:20260515T022828
CREATED:20190924T113636Z
LAST-MODIFIED:20190924T113636Z
UID:22548-1574121600-1574380799@www.pharmajournalist.com
SUMMARY:Gene Therapy Analytical Development
DESCRIPTION:The inaugural Gene Therapy Analytical Development Summit will unite large pharma and innovative biotechs to develop robust analytical tools to guarantee the consistency\, quality and safety of gene therapy products. \n \nFocused specifically on addressing the unique analytical challenges posed by gene therapy vectors\, this technical scientific meeting will unite the ‘boots on the ground’ scientists grappling with these challenges first-hand. \nDelving into technical analytics to assess potency\, capsid integrity\, empty vs full capsids and viral titers of AAV and lentiviral vectors\, this is your opportunity to enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. \nTo learn more and to register online\, visit https://ter.li/z1fc6v
URL:https://www.pharmajournalist.com/event/gene-therapy-analytical-development/
LOCATION:Renaissance Boston Waterfront Hotel 606 Congress Street Boston\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20191126
DTEND;VALUE=DATE:20191128
DTSTAMP:20260515T022828
CREATED:20190918T074903Z
LAST-MODIFIED:20190918T094740Z
UID:22454-1574726400-1574899199@www.pharmajournalist.com
SUMMARY:Targeting RNA Congress
DESCRIPTION:Targeting RNA Congress\n \nNearly 100% of all small molecule drugs in the market are designed to target proteins. However\, only 2% of the human genome actually codes for proteins\, leaving the remaining noncoding DNA and in turn RNA as potentially untapped therapeutic targets. \n \nTo date\, industry has focused on biological products for RNA therapeutics but the emergence of epitranscriptomics and bioinformatics tools has provided the field with a new range of drug modalities. This has led to increasing capital investment alongside collaborations within pharma and biotech to assess if RNA can be a drug target. \nThe Targeting RNA Congress will explore the ‘undruggable’ RNA space and showcases the latest advancements in modulation of RNA directly with small molecules and through epigenetics. The meeting will bring together academic and industry leaders who are building platforms to identify and validate targets in order to assess disease relevance approaches in the RNA world. You’ll take away actionable insights including: \n\n Strategies to go from hit-to-lead candidates\n Addressing structural biology\, biochemical and biophysical attributes relevant for RNA\n Approaches to overcome chemical hurdles associated with new drug discovery platforms\n How mapping RNA upstream regulation can develop disease prevention products\n\n“This meeting is an excellent opportunity to interact with one of the best collections of thought leaders and drug discovery experts in the field of epitranscriptomics\, and I am looking forward to exchanging strategic insights with my colleagues aiming at unlocking an entire class of previously undruggable targets” – Dr. Gerhard Mueller\, Chief Scientific Officer\, Gotham Therapeutics \nTo learn more about Targeting RNA Congress and to register online\, visit: https://go.kisacoresearch.com/l/678123/2019-09-16/ldwx
URL:https://www.pharmajournalist.com/event/targeting-rna-congress/
LOCATION:TBC
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR